Table 3.

Comparison of pro-inflammatory and anti-inflammatory cytokine release during the IGRA test in RTX- or BEL-treated patients and controls.

	Controls (n = 13)	RTX or BEL (n = 28)	P value (RTX or BEL vs. controls)	RTX alone (n = 11)	P value (RTX vs. controls)	BEL alone (n = 17)	P value (BEL vs. controls)	P value (RTX vs. BEL)
TNF-α, pg/ml	135.3 (42.5–319.75)	74.9 (18.2–288.4)	0.69	231.8 (37.3–362.7)	0.776	48.3 (14.4–277.25)	0.398	0.422
IL-6, pg/ml	3425.4 (2083.8–15,043.5)	3972.5 (47.0–7449.67)	0.413	5026 (264.6–7394.7)	0.776	3104.9 (−6.32 to 8862.7)	0.320	0.458
IL-1β, pg/ml	73.4 (19.0–187.45)	65.45 (6.22–141.42)	0.75	121.6 (11.5–173.8)	0.733	58.7 (0.85–129.8)	0.457	0.306
IL-2, pg/ml	245.2 (94.9–538.0)	230.28 (52.7–459.0)	0.588	159.9 (7.14–594.0)	0.459	264.2 (57.9–447.46)	0.812	0.368
IL-10, pg/ml	35.6 (10.65–53.25)	30.0 (1.72–70.3)	0.648	31.5 (−0.1 to 49.6)	0.691	28.5 (1.95–82.15)	0.711	0.963

BEL: belimumab; IL: interleukin; RTX: rituximab; TNF: tumor necrosis factor. Results are expressed as median (Q1–Q3 interquartile range).